555 followers
RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
72 followers
“The objective response rate by RECIST 1.1 was 16%, including a complete response in triple-negative breast cancer. A statistically significant increase in CD8/FoxP3 ratio was seen following the addition of ICIs to entinostat, but not post-entinostat alone
369 followers
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/XYBnufmDhM
192 followers
Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors. https://t.co/TTUQm561a8
7,428 followers
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/dHNRRT7c3g
557 followers
RT @RoisinMConnolly: Looking forward to hearing exciting updates later @RoussosTorres @myESMO! Mini oral ImmunoTx 964MO - Entinostat, nivol…
2,052 followers
RT @RoisinMConnolly: Looking forward to hearing exciting updates later @RoussosTorres @myESMO! Mini oral ImmunoTx 964MO - Entinostat, nivol…
1,598 followers
Looking forward to hearing exciting updates later @RoussosTorres @myESMO! Mini oral ImmunoTx 964MO - Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844) @hopkinskimmel @NCICTEP_ClinRes @UCCResearch
475 followers
RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
6,716 followers
RT @uscnorris: Published in Clinical Cancer Research, USC Norris member Dr. Evanthia Roussos Torres and her colleagues discovered that an i…
391 followers
RT @uscnorris: Published in Clinical Cancer Research, USC Norris member Dr. Evanthia Roussos Torres and her colleagues discovered that an i…
1,036 followers
Published in Clinical Cancer Research, USC Norris member Dr. Evanthia Roussos Torres and her colleagues discovered that an inhibitor affecting gene expression combined with immunotherapy improves response in patients with advanced cancers. Read More: https
134 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
1,321 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
38 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
5,093 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
4,291 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
6,716 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
6,716 followers
RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
28,017 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
881 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
3,602 followers
RT @RoisinMConnolly: Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1…
3,602 followers
Great study! Well done
3,602 followers
RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
1,598 followers
RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
1,598 followers
Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1 trial bridges areas of expertise @hopkinskimmel- #epigenetics #immunotherapy #clinicaltrials. https://t.co/X0mVgB8jka
145 followers
RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
3,461 followers
HDAC inhibitor entinostat with nivolumab {plus minus} ipilimumab in advanced solid tumors. Excellent work @RoussosTorres ! #bcsm
853 followers
RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
391 followers
1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https://t.co/Ntg9CMYjt1
22,054 followers
RT @maryam_lustberg: Including a complete response in #TNBC #bcsm ❗️@OncoAlert @RoisinMConnolly @CCR_AACR
34,256 followers
RT @maryam_lustberg: Including a complete response in #TNBC #bcsm ❗️@OncoAlert @RoisinMConnolly @CCR_AACR
3,082 followers
RT @weldeiry: Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/3bUhX…
877 followers
RT @maryam_lustberg: Including a complete response in #TNBC #bcsm ❗️@OncoAlert @RoisinMConnolly @CCR_AACR
8,747 followers
Including a complete response in #TNBC #bcsm ❗️@OncoAlert @RoisinMConnolly @CCR_AACR
9,796 followers
RT @weldeiry: Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/3bUhX…
14,579 followers
Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/3bUhX0Eisc
6,716 followers
Phase I trial combining histone deacetylase (HDAC) inhibitor #entinostat with #nivolumab ± #ipilimumab in advanced #SolidTumors showed the combination to be safe, tolerable and clinically efficacious. https://t.co/pkJNdqQp5S @RoussosTorres@RoisinMConnolly
6,716 followers
RT @NatRevClinOncol: In a phase I trial of the HDAC inhibitor entinostat plus nivolumab with/without ipilimumab in 33 patients with solid t…
39,990 followers
In a phase I trial of the HDAC inhibitor entinostat plus nivolumab with/without ipilimumab in 33 patients with solid tumours, the ORR was 16%; grade 3–4 AEs included fatigue (21%), anaemia (27%) and neutropenia (12%). https://t.co/pMsMijBZzY #ImmunoOnc #ca
192 followers
Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors. https://t.co/D2vhl3QvsB
994 followers
Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/C8Z2jtroAY
7,428 followers
Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/FjPmKQW2Cp